# Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients

> **NCT00044538** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 102 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** BAY59-8862 (Cytotoxic Taxane)

## Key facts

- **NCT ID:** NCT00044538
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-12
- **Primary completion:** —
- **Final completion:** 2004-06
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2009-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00044538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00044538, "Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00044538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*